Jackson Square Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Jackson Square Capital’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$953K	Hold	63,773	–	–	0.13%	76
2026 Q1	$933K	Hold	63,773	–	–	0.2%	70
2025 Q4	$491K	Hold	63,773	–	–	0.1%	108
2025 Q3	$470K	Hold	63,773	–	–	0.1%	107
2025 Q2	$255K	Hold	63,773	–	–	0.06%	136
2025 Q1	$203K	Hold	63,773	–	–	0.07%	131
2024 Q4	$341K	Hold	63,773	–	–	0.08%	128
2024 Q3	$337K	Hold	63,773	–	–	0.08%	116
2024 Q2	$116K	Hold	63,773	–	–	0.03%	126
2024 Q1	$114K	Hold	63,773	–	–	0.03%	135
2023 Q4	$112K	Hold	63,773	–	–	0.04%	116
2023 Q3	$93.1K	Hold	63,773	–	–	0.04%	107
2023 Q2	$146K	Hold	63,773	–	–	0.06%	111
2023 Q1	$58K	Hold	63,773	–	–	0.03%	106
2022 Q4	$54.2K	Hold	63,773	–	–	0.03%	118
2022 Q3	$52K	Hold	63,773	–	–	0.03%	120
2022 Q2	$63K	Hold	63,773	–	–	0.03%	137
2022 Q1	$105K	Buy	+63,773	New	+$117K	0.03%	177

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jackson Square Capital's CRVS Position: Q2 2026 in Review

Jackson Square Capital held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 63,773 shares worth $953K. The position accounts for 0.13% of the portfolio, ranked #76.

Jackson Square Capital first reported a position in CRVS in Q1 2022 and has held it in 18 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Jackson Square Capital held 63,773 shares of Corvus Pharmaceuticals worth $953K as of Q2 2026.
Jackson Square Capital left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
Corvus Pharmaceuticals made up 0.13% of Jackson Square Capital's portfolio in Q2 2026, its #76 holding.
Jackson Square Capital first reported a position in Corvus Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Jackson Square Capital's 13F filing for Q2 2026, filed 21 Jul 2026.